De novo design of potent and selective mimics of IL-2 and IL-15

We describe a de novo computational approach for designing proteins that recapitulate the binding sites of natural cytokines, but are otherwise unrelated in topology or amino acid sequence. We use this strategy to design mimics of the central immune cytokine interleukin-2 (IL-2) that bind to the IL-2 receptor βγc heterodimer (IL-2Rβγc) but have no binding site for IL-2Rα (also called CD25) or IL-15Rα (also known as CD215). The designs are hyper-stable, bind human and mouse IL-2Rβγc with higher affinity than the natural cytokines, and elicit downstream cell signalling independently of IL-2Rα and IL-15Rα. Crystal structures of the optimized design neoleukin-2/15 (Neo-2/15), both alone and in complex with IL-2Rβγc, are very similar to the designed model. Neo-2/15 has superior therapeutic activity to IL-2 in mouse models of melanoma and colon cancer, with reduced toxicity and undetectable immunogenicity. Our strategy for building hyper-stable de novo mimetics could be applied generally to signalling proteins, enabling the creation of superior therapeutic candidates.A hyper-stable de novo protein mimic of interleukin-2 computationally designed to not interact with a regulatory T-cell specific receptor subunit has improved therapeutic activity in mouse models of melanoma and colon cancer.

[1]  W. Leonard,et al.  The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. , 1995, Immunity.

[2]  T. Honjo,et al.  TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). , 1985, Journal of immunology.

[3]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[4]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[5]  Tyler Hill,et al.  Inclusion of Strep-Tag II in design of antigen receptors for T cell immunotherapy , 2016, Nature Biotechnology.

[6]  Wes McKinney,et al.  Python for Data Analysis , 2012 .

[7]  G. Crooks,et al.  WebLogo: a sequence logo generator. , 2004, Genome research.

[8]  Jens Meiler,et al.  RosettaScripts: A Scripting Language Interface to the Rosetta Macromolecular Modeling Suite , 2011, PloS one.

[9]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[10]  E. Kawasaki,et al.  A general method for facilitating heterodimeric pairing between two proteins: application to expression of alpha and beta T-cell receptor extracellular segments. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. M. Taverna,et al.  Why are proteins marginally stable? , 2002, Proteins.

[12]  B. Kuhlman,et al.  Design of structurally distinct proteins using strategies inspired by evolution , 2016, Science.

[13]  Jamie B. Spangler,et al.  Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers , 2017, eLife.

[14]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[15]  K. Schluns,et al.  The potential and promise of IL-15 in immuno-oncogenic therapies. , 2017, Immunology letters.

[16]  J. Sprent,et al.  The role of interleukin-2 during homeostasis and activation of the immune system , 2012, Nature Reviews Immunology.

[17]  O. Prümmer Treatment-induced antibodies to interleukin-2 , 1997, Biotherapy.

[18]  A. Rudensky,et al.  A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.

[19]  A. Plet,et al.  The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. , 2008, Journal of molecular biology.

[20]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[21]  K. Garcia,et al.  Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. , 2005, Science.

[22]  D. Lauffenburger,et al.  Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.

[23]  Michael J MacCoss,et al.  Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer , 2016, eLife.

[24]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[25]  Piotr Sliz,et al.  Collaboration gets the most out of software , 2013, eLife.

[26]  O. Turriziani,et al.  Neutralizing Antibodies to Interferon-α: Relative Frequency in Patients Treated with Different Interferon Preparations , 1991, The Journal of infectious diseases.

[27]  Interleukin-2 druggability is modulated by global conformational transitions controlled by a helical capping switch , 2020, Proceedings of the National Academy of Sciences.

[28]  Anne S De Groot,et al.  Immunogenicity of protein therapeutics. , 2007, Trends in immunology.

[29]  David Baker,et al.  Proof of principle for epitope-focused vaccine design , 2014, Nature.

[30]  I D Campbell,et al.  The solution structure of the F42A mutant of human interleukin 2. , 1995, Journal of molecular biology.

[31]  A. I. Yakimchik Jupyter Notebook: a system for interactive scientific computing , 2019 .

[32]  T. Darden,et al.  A smooth particle mesh Ewald method , 1995 .

[33]  D. Baker,et al.  Structures and disulfide cross‐linking of de novo designed therapeutic mini‐proteins , 2018, The FEBS journal.

[34]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[35]  R. Puri,et al.  Interleukin-2 toxicity. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[37]  A. D'arcy,et al.  Microseed matrix screening for optimization in protein crystallization: what have we learned? , 2014, Acta crystallographica. Section F, Structural biology communications.

[38]  S. Radford,et al.  Optimizing protein stability in vivo. , 2009, Molecular cell.

[39]  D. Irvine,et al.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. , 2015, Cancer cell.

[40]  W. Greene,et al.  Unexpected effects of the IL-2 receptor alpha subunit on high affinity IL-2 receptor assembly and function detected with a mutant IL-2 analog. , 1993, Journal of immunology.

[41]  Travis E. Oliphant,et al.  Python for Scientific Computing , 2007, Computing in Science & Engineering.

[42]  Clemens Vonrhein,et al.  Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER , 2012, Acta crystallographica. Section D, Biological crystallography.

[43]  A. Ma,et al.  The Pleiotropic Functions of Interleukin 15 , 2000, The Journal of experimental medicine.

[44]  Brian E. Granger,et al.  IPython: A System for Interactive Scientific Computing , 2007, Computing in Science & Engineering.

[45]  V. Ramanan,et al.  A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. , 2016, The New England journal of medicine.

[46]  Shintaro Minami,et al.  MICAN : a protein structure alignment algorithm that can handle Multiple-chains, Inverse alignments, Cα only models, Alternative alignments, and Non-sequential alignments , 2012, BMC Bioinformatics.

[47]  Esteban N. Garza,et al.  Interleukin-2-Dependent Allergen-Specific Tissue-Resident Memory Cells Drive Asthma. , 2016, Immunity.

[48]  V. Pande,et al.  Mechanistic and structural insight into the functional dichotomy between interleukin-2 and interleukin-15 , 2012, Nature Immunology.

[49]  C. Akdis,et al.  Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. , 2011, The Journal of allergy and clinical immunology.

[50]  Robert A. Langan,et al.  De novo design of protein homo-oligomers with modular hydrogen-bond network–mediated specificity , 2016, Science.

[51]  L. Benatuil,et al.  An improved yeast transformation method for the generation of very large human antibody libraries. , 2010, Protein engineering, design & selection : PEDS.

[52]  E. Wherry,et al.  Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo , 2003, Nature Medicine.

[53]  O. Prummer Treatment-induced antibodies to interleukin-2 , 1997 .

[54]  Erwin Laure,et al.  Solving Software Challenges for Exascale , 2014, Lecture Notes in Computer Science.

[55]  W. Leonard,et al.  Cytokine and Cytokine Receptor Pleiotropy and Redundancy* , 2002, The Journal of Biological Chemistry.

[56]  Jamie B. Spangler,et al.  Reprogramming immune proteins as therapeutics using molecular engineering , 2018 .

[57]  Lu Zhang,et al.  Massively parallel de novo protein design for targeted therapeutics , 2017, Nature.

[58]  J. Sprent,et al.  Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells , 2017, Nature Communications.

[59]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[60]  H. Binz,et al.  DARPins: a new generation of protein therapeutics. , 2008, Drug discovery today.

[61]  David Baker,et al.  A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells , 2014, Cell.

[62]  Sergey Lyskov,et al.  PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta , 2010, Bioinform..

[63]  David Baker,et al.  Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes , 2018, Science.

[64]  Jens Meiler,et al.  ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. , 2011, Methods in enzymology.

[65]  K. Wittrup,et al.  Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution , 2015, Proceedings of the National Academy of Sciences.

[66]  H. Wong,et al.  Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model , 2015, Journal of Immunotherapy for Cancer.

[67]  P. Cahan,et al.  Multi-scale cellular engineering: From molecules to organ-on-a-chip , 2020, APL bioengineering.

[68]  Stefan Behnel,et al.  Cython: The Best of Both Worlds , 2011, Computing in Science & Engineering.

[69]  Tianwen Wang,et al.  Incorporation of nonstandard amino acids into proteins: principles and applications , 2020, World Journal of Microbiology and Biotechnology.

[70]  Philip R. Evans,et al.  How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.

[71]  Xuefang Cao Regulatory T cells and immune tolerance to tumors , 2010, Immunologic research.

[72]  Michael Dougan,et al.  Immune therapy for cancer. , 2009, Annual review of immunology.

[73]  Lestat R. Ali,et al.  Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs , 2018, Cancer Immunology Research.

[74]  Timothy A. Whitehead,et al.  Computational Design of Proteins Targeting the Conserved Stem Region of Influenza Hemagglutinin , 2011, Science.

[75]  N. Casadevall,et al.  Pure red-cell aplasia due to anti-erythropoietin antibodies. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[76]  T. Waldmann,et al.  IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. , 1996, Immunity.

[77]  Jean-Christophe Nebel,et al.  Enhancing fragment-based protein structure prediction by customising fragment cardinality according to local secondary structure , 2020, BMC Bioinformatics.

[78]  Ral Garreta,et al.  Learning scikit-learn: Machine Learning in Python , 2013 .

[79]  Daniel-Adriano Silva,et al.  Essentials of de novo protein design: Methods and applications , 2018, WIREs Computational Molecular Science.

[80]  John D. Hunter,et al.  Matplotlib: A 2D Graphics Environment , 2007, Computing in Science & Engineering.

[81]  M. Addepalli,et al.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models , 2016, Clinical Cancer Research.

[82]  M. Smyth,et al.  Cytokines in cancer immunity and immunotherapy , 2004, Immunological reviews.

[83]  M. Bentley,et al.  Chemistry for peptide and protein PEGylation. , 2002, Advanced drug delivery reviews.

[84]  S. Fineberg,et al.  Immunological responses to exogenous insulin. , 2007, Endocrine reviews.

[85]  Berk Hess,et al.  A flexible algorithm for calculating pair interactions on SIMD architectures , 2013, Comput. Phys. Commun..

[86]  S. Rosenberg,et al.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. , 1985, Journal of immunology.

[88]  Otto P mmer Treatment-induced antibodies to interleukin-2 , 1997 .

[89]  Randy J. Read,et al.  Dauter Iterative model building , structure refinement and density modification with the PHENIX AutoBuild wizard , 2007 .

[90]  Ana R. Pacios,et al.  Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2 , 2013, The Journal of Immunology.

[91]  S. A. Marshall,et al.  Rational design and engineering of therapeutic proteins. , 2003, Drug discovery today.

[92]  M. Gavin,et al.  A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy , 2020, Frontiers in Immunology.

[93]  D Baker,et al.  The sequences of small proteins are not extensively optimized for rapid folding by natural selection. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[94]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[95]  Jamie B. Spangler,et al.  Insights into cytokine-receptor interactions from cytokine engineering. , 2015, Annual review of immunology.